Handa Pharmaceuticals, LLC
Prescription medications developed through pharmaceutical R&D
- Sector
- Biotech
- Headquarters
- Fremont, CA
- Founded
- 2005
- Latest Form D
- $2M, Apr 2009
- Total capital
- $2.1M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $2.1M
- 2 Form D · last Apr 2009
- 211 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 8 pending · first 2018
- Rank in peer group#293 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$2M
- Private capital raisedForm D · SEC · 1st filing$31K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#293 · top 20%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Fang-Yu LiuResearcherExecutive OfficerLinked by 3 patents
- Jonathan EmbletonDirectorNamed in SEC Form D filings
- Meifang ChangExecutive OfficerNamed in SEC Form D filings
- Stephen D CaryExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 12- GrantedStable Solid Fingolimod Dosage FormsUSPTOUS 10,925,829
- GrantedStable Fingolimod Dosage FormsUSPTOUS 10,555,902
- GrantedRelease Stable Mesalamine Dosage FormsUSPTOUS 10,098,898
Show all 12 patent records
- Stable Solid Fingolimod Dosage FormsFeb 23, 2021 · US 10,925,829Granted
- Stable Fingolimod Dosage FormsFeb 11, 2020 · US 10,555,902Granted
- Release Stable Mesalamine Dosage FormsOct 16, 2018 · US 10,098,898Granted
- Stable Solid Fingolimod Dosage FormsMar 27, 2018 · US 9,925,138Granted
- Kinase Inhibitor Salts and Compositions ThereofApplication 62685411Pending
- Kinase Inhibitor Salts and Compositions ThereofApplication 62791356Pending
- Kinase Inhibitor Salts and Compositions ThereofApplication 62811368Pending
- Stable Solid Fingolimod Dosage FormsApplication PCTUS2016013938Pending
- Oral Dosage Forms For Delivering Metformin And SitagliptinApplication PCTUS2013022589Pending
- Oral Dosage Forms For Delivering GabapentinApplication PCTUS2011061735Pending
- Oral Formulation For DexlansoprazoleApplication PCTUS2010057280Pending
- Stabilized Atypical Antipsychotic FormulationApplication PCTUS2008075333Pending
Related companies, and why
- Corbus PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
- Tenpoint TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Bit BioSimilar federal contract value in Biotech · null in contracts
- Biophysical Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- AegisCN LLCSimilar federal contract value in Biotech · null in contracts
- SAROS THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .